SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma - Quaterly Results

27 May 2026 Evaluate
A fair growth of 20.78% in the revenue at Rs. 3615.73 millions was reported in the March 2026 quarter as compared to Rs. 2993.57 millions during year-ago period.Net Profit witnessed a 144.53% growth almost the double from Rs. 375.91 millions to Rs. 919.23  millions  of same quarter last year.Operating profit for the quarter ended March 2026 rose to 1334.67 millions as compared to 583.91 millions of corresponding quarter ended March 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 3615.73 2993.57 20.78 13414.76 11743.74 14.23 13414.76 11743.74 14.23
Other Income 274.75 66.36 314.03 1035.33 657.87 57.38 1035.33 657.87 57.38
PBIDT 1334.67 583.91 128.57 4271.00 2738.85 55.94 4271.00 2738.85 55.94
Interest 3.53 3.11 13.50 13.27 11.74 13.03 13.27 11.74 13.03
PBDT 1331.14 580.80 129.19 4257.73 2727.11 56.13 4257.73 2727.11 56.13
Depreciation 87.56 81.77 7.08 342.30 294.52 16.22 342.30 294.52 16.22
PBT 1243.58 499.03 149.20 3915.43 2432.59 60.96 3915.43 2432.59 60.96
TAX 324.35 123.12 163.44 908.45 549.87 65.21 908.45 549.87 65.21
Deferred Tax 23.27 7.54 208.62 45.54 28.43 60.18 45.54 28.43 60.18
PAT 919.23 375.91 144.53 3006.98 1882.72 59.71 3006.98 1882.72 59.71
Equity 453.16 453.16 0.00 453.16 453.16 0.00 453.16 453.16 0.00
PBIDTM(%) 36.91 19.51 89.24 31.84 23.32 36.52 31.84 23.32 36.52

Marksans Pharma Share Price

250.70 1.10 (0.44%)
16-Jun-2026 09:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1801.75
Dr. Reddys Lab 1277.65
Cipla 1387.55
Zydus Lifesciences 1087.80
Lupin 2286.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: